Compare MREO & NSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MREO | NSAI |
|---|---|---|
| Founded | 2015 | 2026 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 47.9M |
| IPO Year | 2017 | 2026 |
| Metric | MREO | NSAI |
|---|---|---|
| Price | $0.30 | $9.94 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $1.96 | N/A |
| AVG Volume (30 Days) | ★ 632.5K | 45.8K |
| Earning Date | 11-09-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $59.51 | N/A |
| Revenue Next Year | $2,326.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $9.82 |
| 52 Week High | $2.37 | $10.00 |
| Indicator | MREO | NSAI |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 55.70 |
| Support Level | $0.27 | $9.82 |
| Resistance Level | $0.35 | $9.94 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 62.55 | 45.45 |
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
NorthStrive Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.